7 completed, 5 unknown, 4 recruiting, 1 terminated. 10 Phase 1, 10 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 3, Recruiting 3, Unknown 3, Terminated 1 |
| Phase 2 | 10 | Completed 4, Recruiting 3, Unknown 3 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow CTL019 chimeric antigen receptor: new trials by email Literature Review of CTL019 chimeric antigen receptor trials Research Report on CTL019 chimeric antigen receptor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus CART19 - SLE, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 24 | 2025-05-06 | 2026-09-24 |
| CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma CART-19 - Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | University of Sao Paulo | 81 | 2024-03-21 | 2024-12-09 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy ARI-0001 cells - Acute Lymphoid Leukemia | Phase 2 | Unknown | Sara V. Latorre | 50 | 2021-05-11 | 2024-06-26 |
| CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) CART-19 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 15 | 2017-10-18 | 2023-11-29 |
| CART-19 Cells For MRD Positive CD19+ ALL CART-19 - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | Fujian Medical University | 20 | 2016-11-01 | 2017-01-23 |
| The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma Cyclophosphamide, Fludarabine, CART-19 - B Cell Lymphoma | Phase 1 | Unknown | Henan Cancer Hospital | 30 | 2016-08-01 | 2017-04-05 |
| Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia CART-19 - Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Beijing Sanwater Biological Technology Co., Ltd. | 20 | 2016-05-01 | 2016-10-14 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2015-12-16 | 2022-06-30 |
| Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia CART-19 - Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options | Phase 2 | Completed | University of Pennsylvania | 42 | 2014-02-27 | 2023-06-22 |
| Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas CART-19 - Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas | Phase 2 | Completed | University of Pennsylvania | 63 | 2014-02-05 | 2023-06-22 |
| Dose Optimization Trial of CD19 Redirected Autologous T Cells CART-19 - Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL | Phase 2 | Completed | University of Pennsylvania | 42 | 2013-01-02 | 2023-06-22 |
| Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma CART-19 - B Cell Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 73 | 2011-08-17 | 2020-03-23 |
| Allo CART-19 Protocol CART-19 - Acute Lymphocytic Leukemia | Phase 1 | Terminated | University of Pennsylvania | 2 | 2010-09-01 | 2020-07-09 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy CART-19 - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | University of Pennsylvania | 26 | 2010-03-17 | 2023-06-22 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Hematologic Neoplasms (1) · Leukemia, B-Cell (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
University of Pennsylvania (6) · Beijing Sanwater Biological Technology Co., Ltd. (1) · Children's Hospital of Philadelphia (1) · Emory University (1) · Fujian Medical University (1) · Henan Cancer Hospital (1) · M.D. Anderson Cancer Center (1) · Nathan Denlinger (1) · SWOG Cancer Research Network (1) · Sara V. Latorre (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1) · University of Sao Paulo (1)
United States (11) · China (4) · Brazil (1) · Spain (1)
Noelle Frey, MD (3) · Brian T Hess (1) · Caitlin Elgarten, MD (1) · David Porter, MD (1) · Diego V Cle, MD, PhD, MBA (1) · Edmund K Waller, MD, PhD (1) · Jianda Hu, 86-13959169016 (1) · Nathan Denlinger, DO (1) · Partow Kebriaei (1) · Stephan A Grupp, MD,PhD (1) · Stephen Schuster, MD (1) · Xiaowen Tang, Ph.D. (1) · Yongping Song (1)
PMID 25317870, PMID 31076448, PMID 31815579, PMID 26813675, PMID 27632680, PMID 29226764, PMID 30178481, PMID 34515338, PMID 41651004, PMID 42341302, PMID 42575986
P30CA138292 (1), U10CA180888 (1)